Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in Recurrent Primary Brain Tumors
NCT03220646Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2017
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib in brain tumor, sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2017; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
brain tumor
Beyond the preview
Go deeper on NCT03220646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03220646.